From November 11-14, 2024, the world's largest annual medical device exhibition, MEDICA 2024, took place in Germany, attracting over 80,000 professional attendees from across the globe. At the exhibition, Wondfo Biotech presented its latest achievements across multiple platforms and product lines, engaging in in-depth discussions with global users and partners to explore innovative solutions for safeguarding health.
 
FC-2100: Compact Design, High-Efficiency Testing
 
"Compact and highly efficient with a built-in screen for convenient use," was the feedback for Wondfo's fully-auto CLIA FC-2100, making its debut at MEDICA 2024. As an innovative addition to Wondfo's chemiluminescence platform, FC-2100 received unanimous praise from professional attendees.



This newly launched CLIA analyzer is designed for precision, efficiency, and flexibility. With a footprint of just 0.64㎡, it fits easily on nearly any laboratory bench, making it ideal for emergency and primary care testing scenarios. FC-2100 offers a testing throughput of 200 tests per hour, with initial results available in just 12 minutes. Features like continuous reagent loading, RFID-enabled automatic project identification, and on-demand testing further enhance its suitability for time-critical diagnostic settings.
 
Currently, Wondfo’s chemiluminescence product line includes nearly 100 testing parameters, covering a broad range of applications such as tumor markers, thyroid markers, cardiac markers, and inflammation markers. Additionally, the product line features specialized tests for coagulation and chronic diseases, including thrombosis, hypertension, and preeclampsia, catering to diverse clinical needs.
 
FS-1000: Easy to Use, Results in Minutes
 
"One-step operation with barcode scanning significantly simplifies workflows and shortens testing time," remarked attendees at MEDICA 2024 about Wondfo's upgraded fluorescence immunoassay platform. Compact and portable, FS-1000 analyzer earned high praise, particularly for its applications in emergency and ICU settings.



Enhanced through multiple technological innovations, the new fluorescence platform offers stronger specificity, improved stability, and full-blood one-step sample addition, optimizing user experience and delivering faster results. The FS-1000 is lightweight and portable, with a rapid testing mode to meet urgent diagnostic needs. Additionally, it features a built-in lithium battery with an impressive 12-hour standby time.
 
Notably, while most cardiac marker tests currently require over 15 minutes for results, Wondfo's new fluorescence platform provides high-sensitivity troponin test results in just 8 minutes, with a detection limit as low as 20 pg/mL, delivering highly sensitive and reliable diagnostics.

Other innovative solutions, including breakthroughs in electrochemistry, colloidal gold, molecular diagnostics, and pathological diagnostics, also garnered significant attention and recognition from professional audiences at the event.
 


Racing for Life, Wondfo has been committed to supporting public health initiatives across more than 150 countries and regions. Wondfo will continue to drive high-quality development through scientific research and innovation, striving to make biotechnology benefit all.